Clinical efficacy of monotherapy of pemetrexed disodium and docetaxel as second-line drug in the treatment of advanced non-small cell lung cancer and its toxic and side effects

FU Na; ZHANG Haijing; LIU Aimei; LI Li

doi:10.7619/jcmp.201715021

FU Na, ZHANG Haijing, LIU Aimei, LI Li. Clinical efficacy of monotherapy of pemetrexed disodium and docetaxel as second-line drug in the treatment of advanced non-small cell lung cancer and its toxic and side effects[J]. Journal of Clinical Medicine in Practice, 2017, (15): 78-80. DOI: 10.7619/jcmp.201715021

Citation:

FU Na, ZHANG Haijing, LIU Aimei, LI Li. Clinical efficacy of monotherapy of pemetrexed disodium and docetaxel as second-line drug in the treatment of advanced non-small cell lung cancer and its toxic and side effects[J]. Journal of Clinical Medicine in Practice, 2017, (15): 78-80. DOI: 10.7619/jcmp.201715021

Citation:

FU Na, ZHANG Haijing, LIU Aimei, LI Li. Clinical efficacy of monotherapy of pemetrexed disodium and docetaxel as second-line drug in the treatment of advanced non-small cell lung cancer and its toxic and side effects[J]. Journal of Clinical Medicine in Practice, 2017, (15): 78-80. DOI: 10.7619/jcmp.201715021

Clinical efficacy of monotherapy of pemetrexed disodium and docetaxel as second-line drug in the treatment of advanced non-small cell lung cancer and its toxic and side effects

Graphical Abstract

Abstract

FullText(HTML)

References (0)

Clinical efficacy of monotherapy of pemetrexed disodium and docetaxel as second-line drug in the treatment of advanced non-small cell lung cancer and its toxic and side effects

Catalog

Export File

Citation

Format

Content